Regentis Biomaterials Ltd. (NYSE American: RGNT) announced that the U.S. Patent and Trademark Office has issued a new patent titled “Organic Solvent Free Compositions Comprising Protein-Polymer Conjugates and Uses Thereof,” covering a liquid, ready-to-use formulation of its lead product, GelrinC, as well as improved production processes that eliminate organic solvents. This patent is significant because it protects the liquid formulation that is designed to conform precisely to cartilage wounds before being cured with UV light to form a temporary elastomeric implant, simplifying surgical procedures and potentially improving patient outcomes.
The patent provides protection for GelrinC through 2038, extending the company's intellectual property portfolio and reinforcing its competitive position in the regenerative medicine market. This comes as Regentis has surpassed 50% enrollment in its pivotal U.S. Food and Drug Administration clinical trial for knee cartilage repair, according to Executive Chairman Dr. Ehud Geller. The progress in clinical enrollment indicates that the company is moving closer to potential commercialization of GelrinC, which aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is currently available.
The liquid formulation represents a key advancement because it eliminates the need for organic solvents in the manufacturing process, making the product more environmentally friendly and potentially reducing production costs. For surgeons, the ready-to-use liquid form allows for easier application, as it can be injected into the defect site and then cured in situ with UV light, providing a precise fit that may enhance tissue regeneration. This technology is based on Regentis' Gelrin platform, which uses synchronized, degradable hydrogel implants to regenerate damaged or diseased tissue, including inflamed cartilage and bone.
The issuance of this patent is a critical milestone for Regentis as it strengthens the company's ability to bring GelrinC to market. With over 50% enrollment in the pivotal trial, the company is on track to generate data that could support FDA approval. If approved, GelrinC could become the first off-the-shelf treatment for knee cartilage repair, offering a cell-free, synthetic alternative to current treatments that often require cell harvesting or multiple surgeries. For more information about Regentis and its technology, visit https://www.regentis.co.il/.
This development highlights the ongoing innovation in regenerative medicine and the potential for new therapies to improve patient quality of life. The full press release is available at https://ibn.fm/bB9os.
